ES2155702T4 - Construcciones expresivas halteroformes para la terapia genetica. - Google Patents

Construcciones expresivas halteroformes para la terapia genetica.

Info

Publication number
ES2155702T4
ES2155702T4 ES97949949T ES97949949T ES2155702T4 ES 2155702 T4 ES2155702 T4 ES 2155702T4 ES 97949949 T ES97949949 T ES 97949949T ES 97949949 T ES97949949 T ES 97949949T ES 2155702 T4 ES2155702 T4 ES 2155702T4
Authority
ES
Spain
Prior art keywords
halteroform
expressive
constructions
construct
genetic therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97949949T
Other languages
English (en)
Other versions
ES2155702T3 (es
Inventor
Burghardt Wittig
Claas Junghans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soft Gene GmbH
Original Assignee
Soft Gene GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soft Gene GmbH filed Critical Soft Gene GmbH
Application granted granted Critical
Publication of ES2155702T3 publication Critical patent/ES2155702T3/es
Publication of ES2155702T4 publication Critical patent/ES2155702T4/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION TRATA DE UNA ESTRUCTURA DE ACIDOS NUCLEICOS QUE SE PUEDE EXPRESAR, QUE CONTIENE LA INFORMACION DE LA SECUENCIA NECESARIA PARA EXPRESAR UN GEN POR EL RNA O LA SINTESIS DE PROTEINAS. TALES ESTRUCTURAS DE EXPRESION SE PUEDEN UTILIZAR EN LA TERAPIA GENICA Y EN LA VACUNACION GENETICA, Y EVITAN MUCHOS DE LOS RIESGOS QUE VAN UNIDOS CON ESTAS ESTRUCTURAS. OTRO ASPECTO DE LA INVENCION ES LA POSIBILIDAD, MEDIANTE UN ENLACE COVALENTE DE LA ESTRUCTURA, P. E. CON PARTICULAS O PEPTIDOS, DE MEJORAR EL TRANSPORTE DE LA ESTRUCTURA EN CELULAS O TEJIDOS.
ES97949949T 1996-11-13 1997-11-13 Construcciones expresivas halteroformes para la terapia genetica. Expired - Lifetime ES2155702T4 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19648625A DE19648625A1 (de) 1996-11-13 1996-11-13 Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

Publications (2)

Publication Number Publication Date
ES2155702T3 ES2155702T3 (es) 2001-05-16
ES2155702T4 true ES2155702T4 (es) 2002-12-16

Family

ID=7812619

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97949949T Expired - Lifetime ES2155702T4 (es) 1996-11-13 1997-11-13 Construcciones expresivas halteroformes para la terapia genetica.

Country Status (8)

Country Link
US (2) US6451593B1 (es)
EP (1) EP0941318B9 (es)
AT (1) ATE198767T1 (es)
AU (1) AU5308698A (es)
DE (3) DE19648625A1 (es)
DK (1) DK0941318T5 (es)
ES (1) ES2155702T4 (es)
WO (1) WO1998021322A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
DE19753182A1 (de) * 1997-11-21 1999-07-29 Claas Junghans Topologisch fixierte matrixgebundene Nukleinsäure
DE19826758C1 (de) * 1998-06-15 1999-10-21 Soft Gene Gmbh Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
EP1165813A2 (en) * 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Linear and circular expression elements
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
GB9924981D0 (en) * 1999-10-21 1999-12-22 Univ Manchester Gene therapy
DE10025920A1 (de) * 2000-05-27 2001-12-06 Mologen Forschungs Entwicklung Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge
DE10119005A1 (de) * 2001-04-18 2002-10-24 Roche Diagnostics Gmbh Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen
WO2002100317A2 (en) 2001-05-25 2002-12-19 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
ES2242888T3 (es) * 2001-10-02 2005-11-16 Mologen Ag Constructo de expresion de adn para el tratamiento de infecciones por leishmaniosis.
US20150050317A1 (en) * 2013-08-19 2015-02-19 Mologen Ag Means for Eliciting an Immune Response and a Method Therefor
EP1432439B1 (de) * 2001-10-02 2005-12-07 Mologen AG Mittel zur verbesserung der immunantwort
WO2003031569A2 (en) * 2001-10-10 2003-04-17 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
AU2003260243A1 (en) * 2002-07-19 2004-03-03 Mologen Ag Dna expression construct for multiple gene expression
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
DE10393824D2 (de) * 2002-09-23 2005-08-11 Mologen Ag Impfstoff gegen Infektionen mit Onkoviren, wie dem felinen Leukosevirus der Katze
WO2004096238A1 (en) * 2003-04-01 2004-11-11 Centocor, Inc. Nucleic acid compositions and methods for use
WO2004111247A1 (de) * 2003-06-10 2004-12-23 Mologen Ag Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
US20050137156A1 (en) * 2003-08-09 2005-06-23 Johnston Stephen A. Methods and compositions for generating an immune response
EP1615663B1 (de) 2003-10-24 2007-12-26 Mologen AG Mittel zur behandlung von infektionen mit leishmanien
PL1699480T3 (pl) 2003-12-30 2011-11-30 Mologen Ag Allogeniczny przeciwnowotworowy czynnik terapeutyczny
US7613295B2 (en) * 2004-02-18 2009-11-03 Harris Corporation Cryptographic device and associated methods
WO2005080567A1 (de) 2004-02-20 2005-09-01 Mologen Ag Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren
US20090004703A1 (en) * 2004-05-28 2009-01-01 Mologen Ag Method for the Production of Suitable Dna Constructs for Specific Inhibition of Gene Expression by Rna Interference
EP1786474B1 (en) * 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
AU2006291429B2 (en) 2005-09-15 2013-04-04 Biontech Delivery Technologies Gmbh Improvements in or relating to amphoteric liposomes
RU2410431C2 (ru) * 2005-11-25 2011-01-27 Мологен Аг Днк-конструкции для специфического ингибирования экспрессии генов посредством рнк-интерференции
CA2665783C (en) 2006-10-13 2015-12-15 Novosom Ag Improvements in or relating to amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
US8883493B2 (en) * 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
DE102007029471A1 (de) 2007-06-20 2008-12-24 Novosom Ag Neue fakultativ kationische Sterole
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
CN104744310A (zh) 2009-07-09 2015-07-01 玛瑞纳生物技术有限公司 包含亚氨基脂质的两性脂质体
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
GB2483462A (en) 2010-09-08 2012-03-14 Mologen Ag Use of a dumbbell-shaped DNA construct for the treatment of cancer through jet-injection administration
GB201021873D0 (en) * 2010-12-23 2011-02-02 Mologen Ag DNA expression construct
JP6298404B2 (ja) 2011-07-25 2018-03-20 オックスフォード ナノポール テクノロジーズ リミテッド 膜貫通ポアを用いる二重鎖ポリヌクレオチド配列決定のためのヘアピンループ方法
WO2013034687A1 (en) 2011-09-09 2013-03-14 Universität Bern Verwaltungsdirektion Avibacterium paragallinarum rtx toxin
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
CA2901545C (en) 2013-03-08 2019-10-08 Oxford Nanopore Technologies Limited Use of spacer elements in a nucleic acid to control movement of a helicase
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
GB201418159D0 (en) * 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
EP3209798B1 (en) 2014-10-23 2022-07-27 Ricardo Mancebo Reagents and methods for isothermal chain reaction
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
GB201509578D0 (en) * 2015-06-03 2015-07-15 Univ Singapore Vectors
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
EP3854419A1 (en) * 2020-01-24 2021-07-28 Univerzita Karlova, Lekarska fakulta v Plzni Dna conjugate and method of transformation of genes into cells
GB202014772D0 (en) 2020-09-18 2020-11-04 Lightbio Ltd Nucleic acid construct
US20240263195A1 (en) 2021-05-11 2024-08-08 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
GB202204112D0 (en) 2022-03-23 2022-05-04 Lightbio Ltd Linear construct

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0690732T3 (da) 1994-01-21 2003-05-19 Powderject Vaccines Inc Gasdrevet genindførselsinstrument
DE4416784A1 (de) * 1994-05-09 1995-11-30 Soft Gene Gmbh Methode zur Anreicherung von Zellen, die durch ballistischen Transfer modifiziert wurden
FR2731014B1 (fr) 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19510696A1 (de) 1995-03-14 1996-09-19 Soft Gene Gmbh Vorrichtung zur Druckverteilung im Kopfstück einer Apparatur zum ballistischen Transfer von Zellen
FR2732971B1 (fr) * 1995-04-13 1997-07-04 Genset Sa Oligonucleotide sens inhibiteur de virus herpes simplex (hsv) a structure en haltere
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer

Also Published As

Publication number Publication date
DK0941318T3 (da) 2001-05-21
WO1998021322A1 (de) 1998-05-22
DE19781276D2 (de) 1999-09-30
US6451593B1 (en) 2002-09-17
US7074772B2 (en) 2006-07-11
ES2155702T3 (es) 2001-05-16
EP0941318B9 (de) 2001-12-19
ATE198767T1 (de) 2001-02-15
DK0941318T5 (da) 2002-02-18
DE19648625A1 (de) 1998-05-14
HK1024714A1 (en) 2000-10-20
DE59702936D1 (de) 2001-02-22
EP0941318B1 (de) 2001-01-17
US20030054392A1 (en) 2003-03-20
EP0941318A1 (de) 1999-09-15
AU5308698A (en) 1998-06-03

Similar Documents

Publication Publication Date Title
ES2155702T4 (es) Construcciones expresivas halteroformes para la terapia genetica.
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
AU7599500A (en) Novel gl50 molecules and uses therefor
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
WO2001075076A3 (en) 33167, a novel human hydrolase and uses therefor
DE60124910D1 (de) Menschliche twik-8 moleküle und ihre verwendung
WO2002020739A3 (en) Human matrix metalloproteinase
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
WO2002024898A3 (en) 47647, a human lipase and uses therefor
MXPA03002557A (es) Interactores de canales del potasio y sus usos.
WO2002029042A3 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
WO2001079293A3 (en) Human cadherin molecules and uses therefor
AU2001285204A1 (en) Atcr-1, a human acyltransferase and uses thereof
WO2002066670A3 (en) 46798, a human matrix metalloproteinase and uses therefor
WO2002029037A3 (en) 57800, a novel human cadherin and uses therefor
WO2002008394A3 (en) 23430, a novel human ubiquitin hydrolase family member and uses therefor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 941318

Country of ref document: ES